Geron Corporation (GERN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Geron Corporation (GERN) has a cash flow conversion efficiency ratio of -0.055x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.58 Million) by net assets ($248.71 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Geron Corporation - Cash Flow Conversion Efficiency Trend (1996–2024)
This chart illustrates how Geron Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Geron Corporation (GERN) total liabilities for a breakdown of total debt and financial obligations.
Geron Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Geron Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beijing UniStrong Science & Technology Co Ltd
SHE:002383
|
0.017x |
|
Tian Jin Motor Dies Co Ltd
SHE:002510
|
0.053x |
|
UP FINT. HLDG (SP.ADR) A
F:1M5
|
N/A |
|
Daoming Optics&Chemical Co Ltd
SHE:002632
|
0.060x |
|
Changsha DIALINE New Material Sci & Tech Co Ltd
SHE:300700
|
-0.041x |
|
Shentong Technology Group Co Ltd
SHG:605228
|
0.079x |
|
Planisware SAS
PA:PLNW
|
0.185x |
|
Indocement Tunggal Prakarsa
JK:INTP
|
0.020x |
Annual Cash Flow Conversion Efficiency for Geron Corporation (1996–2024)
The table below shows the annual cash flow conversion efficiency of Geron Corporation from 1996 to 2024. For the full company profile with market capitalisation and key ratios, see GERN market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $280.32 Million | $-218.62 Million | -0.780x | -15.28% |
| 2023-12-31 | $247.95 Million | $-167.74 Million | -0.677x | +57.51% |
| 2022-12-31 | $80.00 Million | $-127.38 Million | -1.592x | -110.65% |
| 2021-12-31 | $126.42 Million | $-95.56 Million | -0.756x | -139.23% |
| 2020-12-31 | $210.95 Million | $-66.65 Million | -0.316x | +2.57% |
| 2019-12-31 | $135.16 Million | $-43.83 Million | -0.324x | -174.34% |
| 2018-12-31 | $177.73 Million | $-21.01 Million | -0.118x | +40.31% |
| 2017-12-31 | $103.80 Million | $-20.56 Million | -0.198x | -31.94% |
| 2016-12-31 | $122.38 Million | $-18.37 Million | -0.150x | +11.83% |
| 2015-12-31 | $142.13 Million | $-24.20 Million | -0.170x | -338.00% |
| 2014-12-31 | $130.71 Million | $9.35 Million | 0.072x | +111.65% |
| 2013-12-31 | $59.76 Million | $-36.68 Million | -0.614x | +4.66% |
| 2012-12-31 | $85.65 Million | $-55.15 Million | -0.644x | -51.28% |
| 2011-12-31 | $146.60 Million | $-62.39 Million | -0.426x | -85.19% |
| 2010-12-31 | $192.74 Million | $-44.29 Million | -0.230x | +8.56% |
| 2009-12-31 | $172.58 Million | $-43.37 Million | -0.251x | -0.84% |
| 2008-12-31 | $168.46 Million | $-41.98 Million | -0.249x | -92.48% |
| 2007-12-31 | $205.67 Million | $-26.63 Million | -0.129x | +14.63% |
| 2006-12-31 | $173.92 Million | $-26.38 Million | -0.152x | -40.32% |
| 2005-12-31 | $190.71 Million | $-20.61 Million | -0.108x | +49.11% |
| 2004-12-31 | $122.06 Million | $-25.93 Million | -0.212x | +7.43% |
| 2003-12-31 | $106.32 Million | $-24.40 Million | -0.229x | +78.23% |
| 2002-12-31 | $29.74 Million | $-31.34 Million | -1.054x | -189.24% |
| 2001-12-31 | $61.54 Million | $-22.42 Million | -0.364x | -71.18% |
| 2000-12-31 | $63.92 Million | $-13.61 Million | -0.213x | +58.99% |
| 1999-12-31 | $26.20 Million | $-13.60 Million | -0.519x | -118.28% |
| 1998-12-31 | $32.80 Million | $-7.80 Million | -0.238x | +36.49% |
| 1997-12-31 | $21.10 Million | $-7.90 Million | -0.374x | +10.75% |
| 1996-12-31 | $23.60 Million | $-9.90 Million | -0.419x | -- |
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.